Biologics is a product that is produced from living organisms or contain components of living organisms. Biologics are medicines that are developed from blood, proteins, viruses, or living organisms, and are used to prevent, treat, and cure many health conditions. Biologicals are a diverse group of medicines which includes vaccines, growth factors, immune modulators, monoclonal antibodies, as well as products derived from human blood and plasma. The main types of biologics are monoclonal antibodies (MAbs), therapeutic proteins, and vaccines. Monoclonal antibodies, or mAbs, are created in a laboratory to combat a specific infection.  Biologic drugs are the most advanced therapies available for the treatment of a wide range of diseases and conditions. Certain biologic medications are used to treat Crohn's disease, ulcerative colitis, rheumatoid arthritis, and other autoimmune diseases. Biologics have transformed cancer treatment, delayed or reversed the progression of immune-related conditions, transformed the lives of people with rare diseases, and given hope to many patients who previously had no effective treatment options for their condition.

Market Dynamics

Increasing burden of infectious, autoimmune, and chronic diseases, and rising demand for biologics, higher acceptability for innovative therapies, increasing number of clinical trials and research and development activities are the major factors that are expected to drive growth of the global biologics market during the forecast period. Moreover, in March 2022, TG Therapeutics Inc., Biopharmaceutical Company hasannounced  that U.S. FDA extended the prescription drug user fee act (PDUFA) for Instance June 25, 2022, for the Biologics License Application for ublituximab for treatment of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Key features of the study:

• This report provides in-depth analysis of the global biologics market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global biologics market based on the following parameters–company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Novartis AG, AstraZeneca PLC, Bayer AG., Sanofi SA, Pfizer Inc, Merck & Co., Johnson and Johnson, GlaxoSmithKline PLC, Amgen Inc AbbVie Inc, F. Hoffmann-La Roche AG, Eli Lilly and Company, and AGC Biologics.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global Biologics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biologics market

Detailed Segmentation:

• Global Biologics market, By Product:
  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Hormones/Proteins
  • Cellular-based Biologics
  • Gene-based Biologics
  • Others
• Global Biologics market, By Application:
  • Cancer
  • Infectious Diseases
  • Autoimmune Diseases
  • Others
• Global Biologics Market, By Region:
  • North America
    • By Country:
      • U.S.
      • Canada
  • Latin America
    • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country:
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • Novartis AG
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • AstraZeneca PLC
  • Bayer AG
  • Sanofi SA
  • Pfizer Inc
  • Merck & Co
  • Johnson and Johnson
  • GlaxoSmithKline PLC
  • Amgen Inc
  • AbbVie Inc
  • F. Hoffmann-La Roche AG
  • Eli Lilly and Company
  • AGC Biologics

 “*” marked represents similar segmentation in other categories in the respective section.